New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

• Christoph C Zielinski

Affiliations

Christoph C Zielinski

1 Department of Medicine I, Division of Oncology, Medical University of Vienna, Wien, Austria